The protein C pathway: implications for the design of the RESPOND study

por Vangerow, Burkhard, Shorr, Andrew F, Wyncoll, Duncan, Janes, Jonathan, Nelson, David R, Reinhart, Konrad
Publicado 2007

Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease

por Power, Thomas P, Ke, Xuehua, Zhao, Zhenxiang, Bonine, Nicole Gidaya, Cziraky, Mark J, Grabner, Michael, Barron, John J, Quimbo, Ralph, Vangerow, Burkhard, Toth, Peter P
Publicado 2018

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors

por O'Hara, Mark H., Messersmith, Wells, Kindler, Hedy, Zhang, Wei, Pitou, Celine, Szpurka, Anna M., Wang, Dan, Peng, Sheng-Bin, Vangerow, Burkhard, Khan, Anis A., Koneru, Mythili, Wang-Gillam, Andrea
Publicado 2020

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)

por Shorr, Andrew F, Janes, Jonathan M, Artigas, Antonio, Tenhunen, Jyrki, Wyncoll, Duncan LA, Mercier, Emmanuelle, Francois, Bruno, Vincent, Jean-Louis, Vangerow, Burkhard, Heiselman, Darell, Leishman, Amy G, Zhu, Yajun E, Reinhart, Konrad
Publicado 2010